Hematopoietic Stem Cell Transplantation

Overview

Hematopoietic stem cell transplantation (HSCT) is a procedure that replaces a patient's diseased or damaged blood-forming system with healthy hematopoietic stem cells capable of reconstituting all blood cell lineages. It is used to treat hematologic malignancies, marrow failure syndromes, and certain inherited disorders. Transplants are classified as autologous, using the patient's own previously collected cells, or allogeneic, using cells from a related or unrelated donor. The procedure depends on conditioning regimens that suppress disease and the host immune system, followed by infusion of stem cells harvested from bone marrow, mobilized peripheral blood, or umbilical cord blood. Donor selection rests on human leukocyte antigen (HLA) matching, and outcomes are influenced by the degree of HLA compatibility, including the impact of allele-level mismatch and the presence of donor-specific anti-HLA antibodies that can compromise engraftment. Clinical research in this area examines strategies to improve stem cell mobilization, including the use of agents such as plerixafor for rescue collection, and to manage complications that include graft-versus-host disease, delayed immune reconstitution, immune thrombocytopenia, and opportunistic infections such as invasive fungal disease during prolonged neutropenia. Successful transplantation can be curative, but it requires careful donor matching, supportive care, and management of immunologic and infectious risks that define much of the field's ongoing investigation.

Research published in this journal

10 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 10 articles above have been cited 11 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

• CGRP expression and signaling sensitization in a mouse model of chronic oxaliplatin-induced peripheral neuropathy
  2026 · Molecular Pain
• Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
  2023 · Frontiers in Immunology
• Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
  R. Bailén et al. · 2023 · Frontiers in Immunology
• Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation
  2022 · Hematology/Oncology and Stem Cell Therapy
• Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant
  2021 · Frontiers in Immunology
• Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant
  R. Bailén et al. · 2021 · Frontiers in Immunology
• Evaluation of eltrombopag in thrombocytopenia post Hematopoietic cell transplantation: Rertrospective observational trial
  2020 · Hematology/Oncology and Stem Cell Therapy
• Successful Allogeneic Hematopoietic Stem Cell Transplantation from A 5/10 Mismatched Unrelated Donor in A Patient with Donor-Specific Anti-HLA Antibodies.
  2018 · Journal of Hematology and Oncology Research

A sample of recent works citing this journal's research on Hematopoietic Stem Cell Transplantation, linking to each citing work.

This page summarises published research for orientation; it is not medical or professional advice.

Related topics